Gold nanorods attach to, kill bladder cancer cells
April 7, 2014 · Comments Off
Bladder cancer cells overexpress the protein EGFR; gold nanorods can be engineered to attach to EGFR proteins; and then the application of low-intensity laser to the tissue can preferentially heat these gold nanorods, killing the EGFR-rich cancer cells to which they are attached.
Longer life expectancy, aging population necessitate new strategies for prostate cancer care
December 4, 2012 · Comments Off
Members of the University of Colorado Cancer Center recently published a review in the journal Drugs and Aging describing the modern state of prostate cancer care – examining not only new drugs but entirely new classes of drugs that may be effective and well-tolerated in our aging population.
Outliving the Odds
November 30, 2012 · Comments Off
In 20 years, Harry Peterson exhausts his doctor's 'Bag of Tricks," finds hope in a clinical trial.
Enzalutamide adds five months survival in late-stage prostate cancer
August 16, 2012 · Comments Off
Results of a phase III clinical trial of the drug Enzalutamide, published yesterday in the...
Four new drugs will change prostate cancer care, Colorado expert says
February 16, 2012 · Comments Off
3 Key Points Four new drugs could transform prostate cancer from terminal to chronic disease...
New clinical investigations leaders to restructure, streamline Cancer Center’s approach to clinical trials
December 1, 2011 · Comments Off
Two new clinical investigations leaders at the University of Colorado Cancer Center are working to...
New drug treatment extends lives of men with prostate cancer
May 26, 2011 · Comments Off
A drug recently approved by the Food & Drug Administration for the treatment of prostate...
Pre-treating bladder cancer cells increases chemotherapy effectiveness, Cancer Center lab finds
October 22, 2010 · Comments Off
Pre-treating an especially aggressive type of bladder cancer cell more than doubles the effectiveness of...
Bitter melon juice prevents pancreatic cancer in mouse models
October 22, 2010
NTRK1: a new oncogene and target in lung cancer
October 22, 2010
NEJM: Crizotinib Effective in Phase 1 Trial Against ROS1 Lung Cancer
September 30, 2014 · No comments
ALK amc cancer fund American Association for Cancer Research andrew thorburn anthony elias antonio jimeno ASCO biomarkers bladder cancer breast cancer cancer cancer grants cancer research colorado cancer stem cells Cancer Survivorship clinical trial colorado cancer benefit colorectal cancer crizotinib CU Cancer Center Dan Theodorescu fred hirsch funding opportunity grant james degregori jennifer richer leukemia lung cancer lung cancer research melanoma microRNA ovarian cancer Pancreatic cancer paul bunn prostate cancer publications rajesh agarwal ross camidge skin cancer Thomas Flaig tim byers university of colorado cancer center university of colorado hospital university of colorado school of medicine wells messersmith
Another fantastic article by our guest blogger Celia Ruiz Tomlinson. fb.me/2HHwiDGD0
CU Cancer Center researcher looks into female sexual health after cancer treatment. “This is a subject that no... fb.me/6OkYVDAdD
Race for the Cure is tomorrow! We hope to see you there! fb.me/6BZ6FkEi0